Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Electrochemotherapy with bleomycin, oxaliplatin, or cisplatin in mouse tumor models, from tumor ablation to in situ vaccination
Authors:ID Uršič Valentinuzzi, Katja (Author)
ID Kamenšek, Urška (Author)
ID Kranjc Brezar, Simona (Author)
ID Heranney, Chloe (Author)
ID Komel, Tilen (Author)
ID Buček, Simon (Author)
ID Čemažar, Maja (Author)
ID Serša, Gregor (Author)
Files:.pdf PDF - Presentation file, download (18,91 MB)
MD5: 7EF67125763B3465C247C28B50A9DCF8
 
URL URL - Source URL, visit https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1470432/full
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Introduction: In addition to its direct cytotoxic effects, ablative therapies as electrochemotherapy (ECT) can elicit indirect antitumor effects by triggering immune system responses. Here, we comprehensively analyzed this dual effectiveness of intratumoral ECT with chemotherapeutic drugs bleomycin (BLM), oxaliplatin (OXA), and cisplatin (CDDP). Our aim was to determine if ECT can act as in situ vaccination and thereby induce an abscopal effect. By evaluating ECT’s potential for in situ vaccination, our goal was to pave the way for future advancements for its combination with emerging (immuno)therapies, leading to enhanced responses and outcomes. Methods: We employed two mouse tumor models, the immunologically cold B16F10 melanoma and 4T1 mammary carcinoma, to explore both local and systemic (i.e., abscopal) antitumor effects following equieffective intratumoral ECT with BLM, OXA, and CDDP. Through histological analyses and the use of immunodeficient and metastatic (for abscopal effect) mouse models, we identified and compared both the cytotoxic and immunological components of ECT’s antitumor efficiency, such as immunologically recognizable cell deaths (immunogenic cell death and necrosis) and immune infiltrate (CD11+, CD4+, CD8+, GrB+). Results: Differences in immunological involvement after equieffective intratumoral ECT were highlighted by variable kinetics of immunologically recognizable cell deaths and immune infiltrate across the studied tumor models. Particularly, the 4T1 tumor model exhibited a more pronounced involvement of the immune component compared to the B16F10 tumor model. Variances in the antitumor (immune) response were also detected based on the chemotherapeutic drug used in ECT. Collectively, ECT demonstrated effectiveness in inducing in situ vaccination in both tumor models; however, an abscopal effect was observed in the 4T1 tumor model only. Conclusions: This is the first preclinical study systematically comparing the immune involvement in intratumoral ECT’s efficiency using three distinct chemotherapeutic drugs in mouse tumor models. The demonstrated variability in immune response to ECT across different tumor models and chemotherapeutic drugs provides a basis for future investigations aimed at enhancing the effectiveness of combined treatments.
Keywords:electroporation, chemotherapeutic drugs, mouse tumor models
Publication status:Published
Publication version:Version of Record
Submitted for review:25.07.2024
Article acceptance date:24.01.2025
Publication date:11.02.2025
Place of publishing:Lausanne
Publisher:Frontiers Media SA
Year of publishing:2025
Number of pages:str. [1-17]
Numbering:Vol. 16
Source:Lausanne, Switzerland
PID:20.500.12556/DiRROS-23752 New window
UDC:602
ISSN on article:1664-3224
DOI:10.3389/fimmu.2025.1470432 New window
COBISS.SI-ID:226331395 New window
Copyright:by Authors
Note:Nasl. z nasl. zaslona; Opis vira z dne 10. 2. 2025;
Publication date in DiRROS:19.11.2025
Views:166
Downloads:77
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003-2022
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:Z3-2651-2020
Name:Elektrokemoterapija kot in situ vakcinacija

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:elektroporacija, kemoterapevtiki, mišji tumorski modeli


Back